Fazekas, Barbara
Alagesan, Senthilkumar
Watson, Luke
Ng, Olivia
Conroy, Callum M.
Català, Cristina
Andres, Maria Velascode
Negi, Neema
Gerlach, Jared Q.
Hynes, Sean O.
Lozano, Francisco
Elliman, Stephen J.
Griffin, Matthew D. http://orcid.org/0000-0002-8701-8056
Funding for this research was provided by:
National University Ireland, Galway
Article History
Accepted: 22 December 2021
First Online: 10 January 2022
Declarations
:
: All animal procedures were carried out under the license (no. 255/17) from the Animal Experimentation Ethical Committee, University of Barcelona and under authorisation (AE19125/P082 and AE19125/P066) from the Health Products Regulatory Authority, Ireland, and approved by the NUI Galway Animal Care Research Ethics Committee. All procedures were performed in licensed animal facilities at NUI Galway and University of Barcelona.
: Not applicable.
: “The pre-print version of this article is present on ExternalRef removed. This article is not published nor is under publication elsewhere.”
: BF, NN, JQG CC, MVA and MDG have no potential conflicts of interest to declare. SA, LW, ON, CMC and SJE are paid employees of Orbsen Therapeutics Ltd., a cell therapy company that is developing CD362-selected human umbilical cord-derived MSC for clinical applications. FL is founder and ad-honorem scientific advisor of Sepsia Therapeutics.